|
1
|
Abdel-Rahman O: Systemic therapy for
hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl
Canc Inst. 25:165–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harrold JM, Ramanathan M and Mager DE:
Network-based approaches in drug discovery and early development.
Clin Pharmacol Ther. 94:651–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ
and Niu ZF: The role of RhoC in ovarian epithelial carcinoma: A
marker for carcinogenesis, progression, prognosis and target
therapy. Gynecol Oncol. 130:570–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Islam M, Sharma S, Kumar B and Teknos TN:
Atorvastatin inhibits RhoC function and limits head and neck cancer
metastasis. Oral Oncol. 49:778–786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu Y, Chen YC, Sang JR and Xu WR: RhoC
protein stimulates migration of gastric cancer cells through
interaction with scaffold protein IQGAP1. Mol Med Rep. 4:697–703.
2011.PubMed/NCBI
|
|
6
|
Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL,
Yang JQ and Liu HL: Genomic analysis reveals RhoC as a potential
marker in hepatocellular carcinoma with poor prognosis. Br J
Cancer. 90:2349–2355. 2004.PubMed/NCBI
|
|
7
|
Xie S, Zhu M, Lv G, Zhang Q and Wang G:
The role of RhoC in the proliferation and apoptosis of
hepatocellular carcinoma cells. Med Oncol. 29:1802–1809. 2012.
View Article : Google Scholar
|
|
8
|
Xie S, Zhu M, Lv G, Geng Y, Chen G, Ma J
and Wang G: Overexpression of Ras homologous C (RhoC) induces
malignant transformation of hepatocytes in vitro and in nude mouse
xenografts. PLoS One. 8:e544932013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang H, Rudge DG, Koos JD, Vaidialingam B,
Yang HJ and Pavletich NP: mTOR kinase structure, mechanism and
regulation. Nature. 497:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diaz-Padilla I, Duran I, Clarke BA and Oza
AM: Biologic rationale and clinical activity of mTOR inhibitors in
gynecological cancer. Cancer Treat Rev. 38:767–775. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sendur MA, Aksoy S, Zengin N and Altundag
K: Comparative efficacy study of 5-year letrozole or anastrozole in
postmenopausal hormone receptor-positive early breast cancer. J
BUON. 18:838–844. 2013.PubMed/NCBI
|
|
13
|
Khan KH, Yap TA, Yan L and Cunningham D:
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J
Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamanaka K, Petrulionis M, Lin S, Gao C,
Galli U, Richter S, Winkler S, Houben P, Schultze D, Hatano E, et
al: Therapeutic potential and adverse events of everolimus for
treatment of hepatocellular carcinoma-systematic review and
meta-analysis. Cancer Med. 2:862–871. 2013. View Article : Google Scholar
|
|
15
|
Finn RS: Current and future treatment
strategies for patients with advanced hepatocellular carcinoma:
Role of mtor inhibition. Liver Cancer. 1:247–256. 2012. View Article : Google Scholar
|
|
16
|
Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris
DA and Shellman YG: RhoC promotes human melanoma invasion in a
PI3K/Akt-dependent pathway. J Invest Dermatol. 126:862–868. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lehman HL, Van Laere SJ, van Golen CM,
Vermeulen PB, Dirix LY and van Golen KL: Regulation of inflammatory
breast cancer cell invasion through Akt1/PKBα phosphorylation of
RhoC GTPase. Mol Cancer Res. 10:1306–1318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin Z: Experimental research on the
combined effects of RhoC-siRNA and rapamycin in hepatocellular
carcinoma cell line. Master Thesis of Jilin University. 34–36.
2010.
|
|
19
|
Grise F, Bidaud A and Moreau V: Rho
GTPases in hepatocellular carcinoma. Biochim Biophys Acta.
1795:137–151. 2009.PubMed/NCBI
|
|
20
|
Wilson KF, Erickson JW, Antonyak MA and
Cerione RA: Rho GTPases and their roles in cancer metabolism.
Trends Mol Med. 19:74–82. 2013. View Article : Google Scholar :
|
|
21
|
Karlsson R, Pedersen ED, Wang Z and
Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys
Acta. 1796:91–98. 2009.PubMed/NCBI
|
|
22
|
Populo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in cancer
therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Safranek J, Pesta M, Holubec L, Kulda V,
Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska
V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung
tissue of patients with non-small cell lung cancer (NSCLC) and
benign pulmonary disease. Anticancer Res. 29:2513–2517.
2009.PubMed/NCBI
|
|
25
|
Wu MH, Lo JF, Kuo CH, Lin JA, Lin YM, Chen
LM, Tsai FJ, Tsai CH, Huang CY and Tang CH: Endothelin-1 promotes
MMP-13 production and migration in human chondrosarcoma cells
through FAK/PI3K/Akt/mTOR pathways. J Cell Physiol. 227:3016–3026.
2012. View Article : Google Scholar
|
|
26
|
Chaudhary AK, Pandya S, Ghosh K and
Nadkarni A: Matrix metalloproteinase and its drug targets therapy
in solid and hematological malignancies: An overview. Mutat Res.
753:7–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Cheng M and Cao M: Potential
targets for molecular imaging of apoptosis resistance in
hepatocellular carcinoma. Biomed Imaging Interv J.
7:e52011.PubMed/NCBI
|
